Vol. 22/No. 08 | OncologyLive

New Approaches Seek to Meet the Challenge of Graft-Vs-Host Disease

April 28, 2021

Pathways

The curative potential of allogeneic hematopoietic stem cell transplantation for many hematologic malignancies is hindered by the frequent development of graft-vs-host disease, a potentially fatal complication resulting from a complex interaction between donor immune cells in the graft and the host’s immune system.

Landscape for Unresectable HCC Comes Into Sharper Focus

April 27, 2021

Features

After years of stagnation, the paradigm for treating patients with unresectable intermediate-stage or advanced hepatocellular carcinoma is starting to change as a result of novel strategies and evolving views of appropriate patient populations for systemic therapies.

Phase 1/2 Studies Set the Stage for Targeted Combos in B-Cell Lymphomas

April 27, 2021

Features

Although chemotherapy is not likely to lose its place in the frontline treatment of patients with B-cell lymphomas, encouraging data from early-phase studies evaluating the use of targeted agents in combination with and without chemotherapy are capturing the interest of investigators in the field.

RET Inhibition Holds Tumor-Agnostic Potential

April 26, 2021

Features

The development of novel therapies aimed at tumors with RET alterations in non-small cell lung cancer and thyroid cancers sets the stage for a future tumor-agnostic role for this molecularly targeted approach.

Apalutamide Maintains OS Benefit in Castration-Sensitive Prostate Cancer

April 26, 2021

Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.

A Desire to Be a Healer Drives Breast Cancer Expert Forward

April 23, 2021

Sara A. Hurvitz, MD, can remember the exact moment she decided to become an oncologist. It was her first day at the University of Southern California School of Medicine, which she had entered in 1995 without a firm idea of what discipline she wanted to pursue.

Clinical Progress Creates Need for Decision-Support Tools

April 20, 2021

From the Editor

The current endorsement of 3 COVID-19 vaccines in the United States, with several additional products pending FDA review, in less than 1 year from the identification of the structure of the COVID-19 virus is simply remarkable.